Bioheng Therapeutics
PrivateLast Round
Series B
Mar 24, 2021
Total Funding Raised
$97.97M
Company Overview
Bioheng Therapeutics is a biopharmaceutical company that develops allogeneic, off-the-shelf universal CAR-T cell therapies for the treatment of cancer and other diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Bioheng Therapeutics Comparables
Compare Bioheng Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Allotera Therapeutics | 89% | |
| AvenCell | 82% | |
| Century Therapeutics | 78% |
Bioheng Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Mar 24, 2021 | ||||
| Series A | Feb 14, 2019 | ||||
| Angel | Apr 1, 2018 |
Key People
Founding team and executive leadership
Bioheng Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lanchi Ventures | Series B |
| Hillhouse Investment | Series B |
| Lanchi Ventures | Series B |
| GL Ventures | Series B |
| Octagon Capital Advisors | Series B |
| BlueRun Ventures | Series B |
| Octagon Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 16, 2025
Presented latest clinical data for CAR-T product CTD402 at an event.
Bioheng Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Bioheng Therapeutics's valuation, stock price, and market status.
Is BioHeng a public or private company?
BioHeng is a private company.
What is the current stock price of BioHeng?
BioHeng is a private company with no public stock price. No recent secondary market data is available.
How much is BioHeng worth (valuation)?
Valuation information for BioHeng is not publicly available.
Can I buy BioHeng stock?
BioHeng shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was BioHeng's last funding round?
BioHeng's most recent funding round was Series B on March 24, 2021.
Who are the main investors in BioHeng?
Key investors in BioHeng include Hillhouse Investment, GL Ventures, Octagon Capital, Decheng Capital.
Will BioHeng IPO soon?
No public IPO plans have been announced for BioHeng.
How can I track BioHeng secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor BioHeng's secondary market activity and sign up for updates.